{"id":"nct:NCT03356782","kind":"trial","title":"Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas","authors":["Shenzhen Geno-Immune Medical Institute"],"author_count":1,"year":2017,"published":"2017-11-29","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT03356782","source_url":"https://clinicaltrials.gov/study/NCT03356782","archive_url":"https://space-kitty.com/papers/nct:NCT03356782","updated":"2026-08-26","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The aim of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines CAR T cells and IgT cells to treat sarcoma.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Sarcoma","Osteoid Sarcoma","Ewing Sarcoma"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE1, PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"sponsor":"Shenzhen Geno-Immune Medical Institute","conditions":["Sarcoma","Osteoid Sarcoma","Ewing Sarcoma"],"interventions":["BIOLOGICAL: Sarcoma-specific CAR-T cells"],"start_date":"2027-06-01","start_date_type":"ESTIMATED","primary_completion_date":"2029-12-31","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}